Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a hold rating in a report released on Friday, March 9th.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Several other analysts have also commented on ZIOP. HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the company a buy rating in a research note on Monday, March 5th. ValuEngine lowered ZIOPHARM Oncology from a sell rating to a strong sell rating in a research note on Thursday, March 1st. BidaskClub raised ZIOPHARM Oncology from a strong sell rating to a sell rating in a research note on Thursday, January 4th. Finally, Raymond James Financial reissued a hold rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. ZIOPHARM Oncology currently has a consensus rating of Hold and an average price target of $7.50.
Shares of ZIOPHARM Oncology (ZIOP) traded up $0.08 during mid-day trading on Friday, hitting $4.45. The company had a trading volume of 1,253,314 shares, compared to its average volume of 1,417,694. ZIOPHARM Oncology has a 1-year low of $3.33 and a 1-year high of $7.88. The company has a market cap of $622.28, a P/E ratio of -8.24 and a beta of 1.42.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.59 million. During the same period in the previous year, the business posted ($0.11) EPS. ZIOPHARM Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. sell-side analysts predict that ZIOPHARM Oncology will post -0.58 EPS for the current year.
Several institutional investors have recently made changes to their positions in ZIOP. Parametric Portfolio Associates LLC boosted its position in shares of ZIOPHARM Oncology by 6.0% during the second quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock worth $534,000 after buying an additional 4,826 shares during the period. Voya Investment Management LLC boosted its position in ZIOPHARM Oncology by 21.9% during the second quarter. Voya Investment Management LLC now owns 60,782 shares of the biotechnology company’s stock valued at $378,000 after purchasing an additional 10,913 shares during the last quarter. State Street Corp boosted its position in ZIOPHARM Oncology by 12.8% during the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after purchasing an additional 517,057 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in ZIOPHARM Oncology by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock valued at $649,000 after purchasing an additional 7,946 shares during the last quarter. Finally, Adell Harriman & Carpenter Inc. acquired a new position in ZIOPHARM Oncology during the third quarter valued at approximately $141,000. Institutional investors own 40.19% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.